Abstract
Oncoproteomics is the systematic study of cancer samples using omics technologies to detect changes implicated in tumorigenesis. Recent progress in oncoproteomics is already opening new avenues for the identification of novel biomarkers for early clinical stage cancer detection, targeted molecular therapies, disease monitoring, and drug development. Such information will lead to new understandings of cancer biology and impact dramatically on the future care of cancer patients.
In this review, we will summarize the advantages and limitations of the key technologies used in (onco)proteogenomics, (the Omics Pipeline), explain how they can assist us in understanding the biology behind the overarching “Hallmarks of Cancer”, discuss how they can advance the development of precision/personalised medicine and the future directions in the field.
In this review, we will summarize the advantages and limitations of the key technologies used in (onco)proteogenomics, (the Omics Pipeline), explain how they can assist us in understanding the biology behind the overarching “Hallmarks of Cancer”, discuss how they can advance the development of precision/personalised medicine and the future directions in the field.
| Original language | English |
|---|---|
| Pages (from-to) | 611-624 |
| Number of pages | 14 |
| Journal | Clinica Chimica Acta |
| Volume | 495 |
| Early online date | 6 Jun 2019 |
| DOIs | |
| Publication status | Published - Aug 2019 |
Keywords
- Oncoproteomics
- Mass spectrometry
- The hallmarks of cancer
- The omics pipeline
- Personalised/precision medicine